- Home
- » Tags
- » Bavituximab
Top View
- Original Article Tumor-Specific Targeting by Bavituximab, A
- Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic- Labeled Antibody That Binds Exposed Phosphatidylserine Marc Jennewein,1, 2 Matthew A
- PDF of Antibody News
- January 2017 TABLE of CONTENTS
- Endothelial Expression of Autocrine VEGF Upon the Uptake of Tumor-Derived Microvesicles Containing Oncogenic EGFR
- Practice Guidelines: Gastric Cancer1
- ESMO 2016 Congress
- Ian B. Deroock, M.D
- Selected Clinical Trials in Gastric Cancer1
- Bavituximab for Advanced Non-Small Cell Lung Cancer – Second Line in Combination with Docetaxel
- Docetaxel Plus Bavituximab in Previously Treated, Advanced Nonsquamous Non– Small-Cell Lung Cancer
- Clinical Lung Cancer, Vol
- Supplementary Appendix
- Optumrx Brand Pipeline Forecast
- 2020 Medicines in Development ꟷ Cancer
- Pharmaceutical Clinical Trials in New York in State Taxes and More Than $646 Million in Federal • Clinical Trials Are Responsible for 45 to 75 Percent of Taxation
- Assessment of the Evolution of Cancer Treatment Therapies
- Antibody Engineering and Therapeutics, the Annual Meeting Of
- Understanding Cancer Immunotherapy
- Newly Developed Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer
- Monoclonal Antibodies in Non-Small-Cell Lung Cancer
- PATIENT RESOURCE Monoclonal Antibodies
- Novel Agents and Future Prospects in the Treatment of Pancreatic Adenocarcinoma Highlights from the “2013 ASCO Annual Meeting”
- Disease Control and Objective Responsive Rates in Randomized
- OHC Clinical Trials List V4
- Oncology Drugs in the Pipeline
- A Phase I/II Study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- Central Nervous System Tumors
- Monoclonal Antibodies: an Emerging Class of Therapeutics in Non Small Cell Lung Cancer
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- OHC Clinical Trials List 080315
- Research Report
- Optumrx Brand Pipeline Forecast
- Tumor-Targeted Drug Conjugates As an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
- Theranostics Targeting Phosphatidylserine for Cancer
- (INN) for Biological and Biotechnological Substances
- Ramesh Rengan, MD Ph.D. Radiation Therapy Contraindications And
- Medicines & Vaccines in Development for Cancer
- Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors
- Oncology Drugs in the Pipeline
- Timepoint 1 Geting Assembly Complexes (Attacs) for Selectively Activating De¬ Sired Immune Cells in the Tumor Microenvironment
- OHC Clinical Trials List V3 06112014